Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.78 |
| ▸ | MEN1 | O00255 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalidixic Acid SCHEMBL7878858 | 0.88 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| SCHEMBL12248454 | 0.88 | KMT2A (0.80) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL29367723 | 0.88 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL21736 | 0.88 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| SCHEMBL13174430 | 0.87 | KMT2A (0.74) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL4766415 | 0.86 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL9743582 | 0.86 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| SCHEMBL13623579 | 0.86 | KMT2A (0.78) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL950987 | 0.86 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL27256972 | 0.86 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | KMT2A 2302/4885MEN1 2872/4885LMNA 1672/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | KMT2A 2302/4885MEN1 2872/4885LMNA 1672/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | KMT2A 2312/4885MEN1 2870/4885LMNA 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.